Bontempo Ohly Capital Mgmt LLC Increases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Bontempo Ohly Capital Mgmt LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 0.8% in the 2nd quarter, Holdings Channel.com reports. The fund owned 14,650 shares of the company’s stock after acquiring an additional 115 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Bontempo Ohly Capital Mgmt LLC’s investment portfolio, making the stock its 26th biggest position. Bontempo Ohly Capital Mgmt LLC’s holdings in Johnson & Johnson were worth $2,141,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Texas Capital Bank Wealth Management Services Inc increased its position in shares of Johnson & Johnson by 25.6% during the second quarter. Texas Capital Bank Wealth Management Services Inc now owns 4,997 shares of the company’s stock worth $730,000 after purchasing an additional 1,019 shares in the last quarter. Texas Capital Bancshares Inc TX grew its holdings in shares of Johnson & Johnson by 26.3% during the second quarter. Texas Capital Bancshares Inc TX now owns 5,268 shares of the company’s stock worth $770,000 after buying an additional 1,096 shares in the last quarter. Peloton Wealth Strategists raised its position in shares of Johnson & Johnson by 3.1% in the second quarter. Peloton Wealth Strategists now owns 16,749 shares of the company’s stock valued at $2,448,000 after buying an additional 496 shares during the last quarter. Security National Bank of SO Dak lifted its stake in shares of Johnson & Johnson by 1.8% in the second quarter. Security National Bank of SO Dak now owns 18,264 shares of the company’s stock worth $2,669,000 after buying an additional 315 shares in the last quarter. Finally, Smith Thornton Advisors LLC acquired a new position in Johnson & Johnson during the second quarter worth about $522,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 23rd. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Friday, September 20th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Trading Up 0.0 %

Shares of JNJ stock opened at $161.40 on Friday. The company has a 50-day moving average of $162.15 and a two-hundred day moving average of $154.21. The firm has a market cap of $388.44 billion, a PE ratio of 10.06, a price-to-earnings-growth ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter last year, the firm earned $2.80 EPS. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.